2021 Mantle Cell Lymphoma Scientific Workshop
April 6-8, 2021
Agenda | Virtual Event

NOTE: All agenda times are Eastern U.S. Other common time zones in red.

10:00-10:15am Welcome and Introductions (7am PST, 9am CST, 4pm CET)
Meghan Gutierrez, Chief Executive Officer, Lymphoma Research Foundation
Martin Dreyling, MD, PhD, Chair, LRF MCL Consortium Executive Committee

10:15-11:15am Keynote Address
Elaine S. Jaffe, MD, National Cancer Institute

11:15-11:20am Stretch Break

11:20-12:35pm Mantle Cell Lymphoma (MCL) Biology I (8:20am PST, 10:20am CST, 5:20pm CET)
Moderator: Leticia Quintanilla-Fend, MD, University of Tuebingen

E3 Ligase UBR5 HECT domain mutations in lymphoma control maturation of B cells via aberrant splicing
Shannon Buckley, PhD, University of Nebraska Medical Center

Genomic and epigenomic insights into the origin, pathogenesis and clinical behavior of mantle cell lymphoma
Elias Campo, MD PhD, Hospital Clinic Barcelona – IDIBAPS

Long-read sequencing reveals a complex CCDN1 rearrangement and haplotype-specific methylation in a case of non-nodal leukemic MCL
Johannes Hellmuth, MD, University Hospital LMU Munich

Cyclin D1 activates a transcriptional program relevant for mantle cell lymphoma pathogenesis
Pedro Jares, PhD, Hospital Clinic Barcelona – IDIBAPS

12:35-1:05pm 30 min Lunch Break

1:05-2:20pm MCL Biology II (10:05am PST, 12:05pm CST, 7pm CET)
Moderator: Pedro Jares, PhD, Hospital Clinic Barcelona – IDIBAPS
Metabolomic and Fluxomic Study of Mantle Cell Lymphoma Bionetwork: Metabolic Insights as Guidance to Detect and Overcome BTKi Resistance
Alexander Shestov, PhD, University of Pennsylvania

The role of CEACAM1 in BCR signaling and immunotherapy in mantle cell lymphoma
Vu Ngo, PhD, City of Hope

Dynamic Changes in Gene Mutational Landscape with Preservation Of Core Mutations in Mantle Cell Lymphoma
Mariusz Wasik, MD, Fox Chase Cancer Center

Cannabinoids reduce malignant B-cells and affect non-malignant leukocytes in the blood of patients with indolent B cell leukemia
Birgitta Sander, MD, PhD, Karolinska Institutet

2:20-2:25pm  Stretch Break

2:25-3:50pm  MCL Novel Pathways and Targets (11:25am PST, 1:25pm CST, 8:25pm CET)
Moderator: Eduardo M. Sotomayor, MD, George Washington Univ. Cancer Center

Stromal cell signaling reprogramming as a novel vulnerability for combination therapies to overcome immune suppression in mantle cell lymphoma
Michael Jain, MD, PhD, Moffitt Cancer Center

Chimeric Antigen Receptor T Cells Targeting Clonally Restricted Lambda Light Chain Surface Immunoglobulin Eradicate Mantle Cell Lymphoma
Raghuveer Ranganathan, MD, University of Southern California

Time-resolved scRNA-seq of ibrutinib-treated mantle cell lymphoma cell line reveals the heterogeneous cellular behaviour to drug treatment
Hilka Rauert-Wunderlich, PhD, University of Wuerzburg Institute of Pathology

Targeting Transcriptional Programming Disables and Overcomes the Evolution of Ibrutinib-Resistance in Mantle Cell Lymphoma
Bijal Shah MD, MS, Moffitt Cancer Center

XLA immunophenotype in MCL patients attaining a prolonged complete response to the selective BTK inhibitor, tirabrutinib
Harriet Walter, MD, PhD, University of Leicester

3:50–4:00 pm  Day 1 Wrap Up
**Novel Targets and Therapies/ Personalization of Therapy (7am PST, 9am CST, 4pm CET)**

**Moderator:** Leo I. Gordon, MD, FACP, Robert H. Lurie Comprehensive Cancer Center, Northwestern University

*Molecular Heterogeneity and Tumor-Immune Evolution in Refractory Mantle Cell Lymphoma*
Vivian Jiang, PhD MD, Anderson Cancer Center

*Class B and class C CpG deoxynucleotide-conjugated gold nanoparticles for treatment of mantle cell lymphoma*
Adam Lin, MD, PhD, Northwestern University

*Exploiting the epigenetic and mRNA splicing regulator PRMT5, as a novel therapeutic target in mantle cell lymphoma*
Yixin Yao, PhD, MD, Anderson Cancer Center

*Effects of Proteasome Inhibitors in the Anti-Tumor Activity of Venetoclax in Mantle Cell Lymphoma Pre-clinical Models*
Shalin Kothari, MD, Yale University

**Stretch Break**

**Minimal Residual Disease in MCL (8:20am PST, 10:20am CST, 5:20pm CET)**

**Moderator:** Kami Maddocks, MD, The Ohio State University

*Comparative analysis of standardized IG-based ASO qPCR, ddPCR and amplicon NGS for MRD monitoring in Mantle cell lymphoma*
Christiane Pott, MD, University Hospital Schleswig-Holstein

*Utility of NGS-based MRD Assessments in a Frontline Lenalidomide-based Chemoimmunotherapy Treatment Approach*
Zachary Epstein-Peterson, MD, Memorial Sloan Kettering Cancer Center

*Ibrutinib Maintenance (I-M) in Mantle Cell Lymphoma (MCL) Following Frontline Intensive Induction: Interim Response, Sequential MRD and Safety Evaluation*
Reem Karmali, MD, Northwestern University

*Assays for Circulating Tumor DNA Predict Survival and Often Precede Clinical Relapse in Mantle Cell Lymphoma*
Rahul Lakhotia, MD, National Heart, Lung, and Blood Institute

*Minimal Residual Disease (MRD) Assessment in the ECOG1411 Randomized Phase 2 Trial of Front-Line Bendamustine-Rituximab (BR)-Based Induction Followed By Rituximab (R) ± Lenalidomide (L) Consolidation for Mantle Cell Lymphoma (MCL)*
Mitchell Smith, MD, PhD, Member, ECOG-ACRIN
Roundtable Discussion: MRD in MCL

12:50-1:20pm  30 min Lunch Break

1:20-2:45pm  MCL Therapeutic Resistance/ Prognostic and Predictive Biomarkers/ Epidemiology and Outcomes (10:20am PST, 12:20pm CST, 7:20pm CET)
Moderator: Peter Martin, MD, Weill Cornell Medicine

Update on SOX11 inhibitors for MCL
Samir Parekh, MD, Icahn School of Medicine at Mount Sinai

Evolving Frontline Immunochemotherapy for Mantle Cell Lymphoma and the Impact on Survival Outcomes
Yucai Wang, MD, PhD, Mayo Clinic, Rochester

A modified scoring system exhibits high efficacy in predicting the prognosis of patients with mantle cell lymphoma: initial report from the North American Mantle Cell Lymphoma Consortium of 23 Institutions
Chengfeng Bi, MD, PhD, University of Nebraska Medical Center

Molecular Profiling and Preclinical Drug Efficacy to Interrogate Dysregulated Pathways for Precision Medicine in Mantle Cell Lymphoma
Yang Liu, PhD, MD, Anderson Cancer Center

2:45-2:55pm  Day Two Wrap Up

2:55-3:15pm  MCL Leadership Award | Dr. Michael Williams

3:30-5:30pm  2021 Spring SAB Meeting (LRF Scientific Advisory Board members only)
(12:30pm PST, 2:30pm CST)

Thurs, April 8

10:00-11:30 am  Clinical Trials in MCL I (7am PST, 9am CST, 4pm CET)
Moderator: Michael Williams, MD, MSc, University of Virginia Cancer Center

R-MACLO-IVAM is an effective regimen to induce long term remission in untreated mantle cell lymphoma (MCL)
Juan Alderuccio, MD, Sylvester Comprehensive Cancer Center, University of Miami

Clinical Outcome of Mantle Cell Lymphoma Patients with High Risk Biology (high Ki-67, blastic MCL, or high p53 expression)
Martin Dreyling, MD, PhD, University Hospital LMU Munich
A pilot study of acalabrutinib with bendamustine/rituximab followed by cytarabine/rituximab (R-ABC) for untreated mantle cell lymphoma
Daniel Guy, MD, Providence Cancer Institute

Frontline treatment with ibrutinib with rituximab (IR) combination is highly effective in elderly (≥65 years) patients with mantle cell lymphoma (MCL) – results from a phase II trial
Preetesh Jain, MD, PhD, MD Anderson Cancer Center

KTE-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients With Relapsed/Refractory Mantle Cell Lymphoma: Results of the Phase 2 ZUMA-2 Study
Michael Wang, MD MD Anderson Cancer Center

11:30-11:35 am  Stretch Break

11:35 -12:35pm  Clinical Trials in MCL II (8:35am PST, 10:35am CST, 5:35pm CET)
Moderator: Martin Dreyling, MD, PhD, University Hospital LMU Munich

NCTN Update in MCL: Current and Planned Studies
Brad Kahl, MD, Washington University School of Medicine

European MCL Network: Current Study Generation
Martin Dreyling, MD, PhD, University Hospital LMU Munich

12:35 – 1:05pm  30 min Lunch Break

1:05-2:05 pm  COVID-19 and Mantle Cell Lymphoma (10:05am PST, 12:05pm CST, 7:05pm CET)
Update from LRF COVID Vaccine and Lymphoma Panel
Andrew D. Zelenetz, MD, PhD, Memorial Sloan Kettering Cancer Center

COVID-19 in Patients Receiving CD20-Depleting Immunochemotherapy for B-Cell Lymphoma
Oliver Weigert, MD, University Hospital LMU Munich

2:05-2:50pm  Collaborative Discussion: Upcoming MCL Clinical Trials
Moderator: Martin Dreyling, MD, PhD, University Hospital LMU Munich
Attendees will be invited to give a brief overview of any upcoming clinical trials and requests for collaboration as part of an open mic discussion.

2:50-3:00 pm  Michael Williams MD Abstract Award Winners Announced

3:00-3:30pm  MCL Workshop Concluding Remarks (12:05pm PST, 2:05pm CST, 9:05pm CET)
Martin Dreyling, MD, PhD, MCL Consortium Executive Committee Chair
University Hospital LMU Munich